Short articles
Abstract
The note deals with the Pfizer case, where the pharmaceutical company was condemned for an abuse of dominant position relating to otherwise lawful patent practices which, in the Authority's representation, had delayed without merit entry by generic producers. The note takes this opportunity to comment on the system of judicial review of the Italian Competition Authority's antitrust decisions, comparing it with the equivalent system at the EU level. The note also reviews more in-depth the judgment with reference to both those areas where the Court decided to take a specific position and in those where it omitted doing so.
Keywords
Antitrust, EU, Abuse of Dominant Position, Patents, Judicial Review, Commitments
Full Text:
PDFNBN: http://nbn.depositolegale.it/urn%3Anbn%3Ait%3Aagcm-15193
DOI: http://dx.doi.org/10.12870/iar-11058
References
Antitrust & Public Policies
ISSN: 2284-3272
Iscrizione al Tribunale di Roma n. 300, del 12 dicembre 2013, modificata con registrazione n. Reg. Certificati 216 bis/2019
Last issue published on December 30, 2019